首 页   本刊简介  编委会  审稿专家  在线期刊  写作规范  广告合作  联系我们
您现在的位置:首页 => 在线期刊 => 2017年 4期肝胆胰疾病的微创治疗 => 综述 =>妊娠期应用替比夫定降..
妊娠期应用替比夫定降低HBV母婴传播风险的研究进展
Research advances in the application of telbivudine during pregnancy to prevent HBV mother-to-child transmission
文章发布日期:2017年03月07日  来源:  作者:王崇,曹梦琢,王川,等  点击次数:1709次  下载次数:379次

调整字体大小:

(此处下载失败可以在在线预览处保存副本或者右键另存为)

【摘要】:HBV DNA高载量孕妇分娩的新生儿即使接受乙型肝炎疫苗联合免疫阻断预防治疗后仍有10%的HBV感染率。对于HBV DNA高载量孕妇群体临床开始尝试于孕中晚期应用核苷和核苷酸类药物(拉米夫定、替比夫定和替诺福韦)以提高乙型肝炎母婴传播阻断效果。对HBV DNA高载量孕妇妊娠晚期使用替比夫定的抗病毒治疗策略、抗病毒治疗后母体HBV DNA水平变化情况、是否能继续提高母婴传播阻断成功率、母婴双方的安全性、最佳服药和停药时间及母乳喂养等方面作一综述。
【Abstract】:Almost 10% of neonates whose mothers have a high HBV DNA load may have HBV infection, even after the preventive treatment with hepatitis B vaccine and immune interruption. In pregnant women with a high HBV DNA load, nucleos(t)ide analogues (lamivudine, telbivudine, and tenofovir) have been used in the second and third trimesters to improve the interruption of mother-to-child transmission of hepatitis B. This article reviews the strategies for antiviral therapy with telbivudine for pregnant women with a high HBV DNA load in their third trimester, changes in maternal HBV DNA level after antiviral therapy, whether the success rate of interruption of mother-to-child transmission can be further increased, safety in mothers and infants, the most appropriate time for drug administration and withdrawal, and breastfeeding issues.
【关键字】:肝炎病毒, 乙型; 疾病传播, 垂直; 治疗; 孕妇; 综述
【Key words】:hepatitis B virus; disease transmission, vertical; therapy; pregant women; review
【引证本文】:王崇, 曹梦琢, 王川, 等. 妊娠期应用替比夫定降低HBV母婴传播风险的研究进展[J]. 临床肝胆病杂志, 2017, 33(4): 746-750.

地址:长春市东民主大街519号《临床肝胆病杂志》编辑部 邮编:130061 电话:0431-88782542/3542
临床肝胆病杂志 版权所有 Copyright © 2009 - 2013 Lcgdbzz.org. All Rights Reserv 吉ICP备10000617号

吉公网安备 22010402000041号